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OBJECTIVES: Denosumab is a human monoclonal antibody against receptor acti-
vator of nuclear factor-kB ligand (RANKL), which can be used for osteoporosis as an 
antiresorptive agent. The aim of this study was to evaluate the efficacy and safety 
of denosumab for the treatment of postmenopausal osteoporosis by performing 
a meta-analysis. METHODS: Pubmed, EMBASE, the Cochrane Central Register 
of Controlled Trials, and other trial registries through July 2014 were searched. 
Inclusion criteria were randomized, placebo-controlled clinical trials on patients 
with postmenopausal osteoporosis, 60mg of denosumab every 6 months, con-
sistent time framework, and derivable outcomes for incidences of new vertebral, 
nonvertebral fractures, and adverse events. A meta-analysis using fixed-effects 
model was conducted to calculate pooled relative risks with a 95% confidence 
interval. Heterogeneity across studies was also assessed. RESULTS: Six RCTs 
involving 9134 patients were included. The results showed that denosumab was 
associated with a significant reduction in new vertebral fractures risk (RR= 0.325, 
95%CI 0.256 to 0.412, p< 0.001). A decreased risk of nonvertebral fractures was also 
observed (RR= 0.789, 95%CI 0.670 to 0.928, p= 0.004). As compared to the placebo 
arm, the denosumab arm showed no evidence of significant risk of total adverse 
events [RR= 1.003, 95%CI 0.991 to 1.015], serious adverse events [RR= 1.042, 95%CI 
0.967 to 1.124], and fatal adverse events [RR= 0.785, 95%CI 0.557 to 1.067]. In addi-
tion, the incidence rates of all treatment-related adverse events and dropouts 
due to adverse events were not significant between the denosumab and placebo 
arms. CONCLUSIONS: The efficacy of denosumab on fracture risk reduction and 
its safety has not yet been systematically proved. However, results of this meta-
analysis showed that denosumab was associated with a significant reduction in 
the risk of vertebral and nonvertebral fractures in patients with postmenopausal 
osteoporosis. No evidence of increased risk in serious, fatal and all treatment-
related adverse events were detected.
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OBJECTIVES: Describe the adverse drug reactions (ADR) and their incidence in 
patients with rheumatoid arthritis who were treated in the Colombian Heath 
System. METHODS: Retrospective cohort study using information from all 
patients who were diagnosed with rheumatoid arthritis and attended Specialized 
Institution centers in the cities of Bogotá, Cali, Manizales, Medellin and Pereira 
between December 1st, 2009 and August 30th, 2013. The ADRs were obtained from 
medical records and the pharmacovigilance system register and were sorted by 
frequency and affected tissue according to WHO Adverse Reaction Terminology 
(WHO-ART). RESULTS: A total of 949 ADR reports were obtained from 419 patients 
with an incidence of 32.8 ADRs per 100 patient-years; these were from a cohort 
of 1,364 users followed for an average of 23.8±12.9 months. There was a female 
preponderance (n= 366, 87.4%) and a mean age of 52.7±13.1 years. The high-
est incidence rates for ADRs were reported for tocilizumab, rituximab and inf-
liximab with 28.8, 23.1 and 13.3 reports per 100 patient-years respectively. The 
most frequent were “Elevated transaminase levels” and “Dyspepsia”. Overall, 
87.7% of ADRs were type A; 36.6% were classified as mild, 40.7% as moderate 
and 22.7% were severe. As a result, 73.2% of patients who experienced an ADR 
stopped taking their drugs. CONCLUSIONS: the occurrence of ADRs in patients 
treated for rheumatoid arthritis is common, especially in those associated with 
the use of biotechnologically produced anti-rheumatic drugs. This should be 
emphasized in reports and monitoring is needed to reduce the risks in these 
patients.
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OBJECTIVES: Patients with low-energy hip fracture represent a high-risk group 
for subsequent hip fractures. Our nationwide study focused on the effect of 
demographic and clinical factors on the risk of contralateral hip fractures in 
Hungarian men over 60 years. METHODS: The retrospective observational 
cohort study based on data of the Hungarian National Health Insurance Fund. 
Men aged 60 years and over diagnosed with primary femoral neck fracture in 
year 2000 were included in the study. The incidence of contralateral fractures 
was investigated between 01 January 2000 and 31 December 2008. Occurrence of 
secondary hip fractures was analyzed in relation to patients’ age, place of living, 
hospital providing treatment for primary hip fracture, type of primary fracture, 
comorbidities, type of surgical intervention for primary fracture and survival 
time. To evaluate the prognostic factors multivariate Cox proportional hazard 
regression and Kaplan-Meier survival analysis were used. RESULTS: 917 patients 
matched the study criteria. 49 secondary fractures (5.34%) occurred during the 
observation period. The incidence density of secondary fractures was 0.13 cases 
per person-year, and the annual distribution showed that the highest incidence 
occurred in the second year (1.21%). Increasing age (years, HR: 1.06, p= 0.001, CI: 
1.02- 1.09) and place of living (town vs. village, HR: 2.82, p= 0.022, CI: 1.16- 6.84) 
were found as risk factor of subsequent hip fractures. Log rank test revealed no 
significant difference (p= 0.056) between the survival time of patients living in 
village (mean survival time: 1456 days) and in towns (mean survival time: 1481 
days). CONCLUSIONS: We demonstrated the increased risk of subsequent hip 
fracture in men with higher age and living in towns. Considering that there was 
no difference in the survival time, there is a need to identify lifestyle factors influ-
encing the incidence of subsequent hip fractures in men living in village and in 
towns.
27 systematic reviews and health technology assessments were included, 30 clinical 
trials were extracted which the control and intervention arms were treated with 
methotrexate. The results of mixed treatment comparison revealed that tofacitinib 
displays similar safety than adalimumab, certolizumab, infliximab, etanercept, goli-
mumab, rituximab, tocilizumab and abatacept in occurrence of serious adverse 
events and serious infections due to not having statistically significance differences. 
In the outcome of withdrawal due to adverse events, etanercept showed less prob-
ability of occurrence than tofacitinib (OR= 2.21, IC95%: 1.02-4.03), regarded to other 
biological DMARDs, they presented the same risk than tofacitinib. CONCLUSIONS: 
The results of mixed treatment comparison indicated that tofacitinib is similarly 
safe than biological DMARDs considering the occurrence of serious adverse events 
and serious infections.
PMS3
fActorS And reASonS ASSociAted With SWitching in rheuMAtoid 
ArthritiS PAtientS exPerienced on Biologic dMArdS And iMPAct on 
heAlth cAre reSource utilziAtion in An integrAted heAlthcAre 
SySteM
Rashid N.1, Patel C.2, Li Z.1, Guerrero V.1, Nadkarni A.2, Aranda G.2
1Kaiser Permanente, SCAL Region, Downey, CA, USA, 2BMS, Plainsboro, NJ, USA
OBJECTIVES: Evaluate factors and reasons associated with switching from bio-
logic disease-modifying anti-rheumatic drugs (bDMARD) in Kaiser Permanente 
Southern California (KPSC) experienced RA patients; evaluate RA related health 
care resource utilization (HCRU) and costs associated with bDMARD switch-
ing. METHODS: A retrospective database study was conducted using KPSC 
patients greater than or equal to 18 years of age and with a diagnosis of RA (ICD-9 
714.xx). The identification period was from 01/01/2009 to 12/31/2012. The index 
date was defined as the first identified bDMARD prescription during the identi-
fication period. Patients were on the same index bDMARD for 24 months prior 
to index date and were followed up for 12 months post-index. Patients were cat-
egorized into a switch and a non-switch group during follow up. A multivariate 
regression analysis was conducted to evaluate factors associated with patients 
switching versus not switching. Chart notes were reviewed 30 days prior and 30 
days post switch date to identify reasons for switching. RA related HCRU and costs 
were calculated for 12 months pre/post-index for both groups. RESULTS: 1,753 
patients were identified (5% switchers, and 95% non-switchers). Factors associated 
with bDMARD switching were: obesity, Charlson comorbidity index (CCI) score ≥ 2, 
narcotics or NSAIDS use, non-adherence, and higher outpatient use in the prior 
6 months. Over 40% of patients switched due to adverse events, lack or loss of 
efficacy. Patients who switched had higher RA related pre/post-index outpatient 
visits and higher 12 months pre/post-index outpatient visit costs versus those 
patients that did not switch. CONCLUSIONS: Previous studies have evaluated 
bDMARD switching patterns in RA patients; however these unique data from this 
integrated healthcare system highlights reasons associated with bDMARD switch-
ing. Reasons associated with bDMARD switching included medication adverse 
events, and lack/loss of efficacy. RA Patients who switched bDMARD had higher 
RA related outpatient HCRU and costs.
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OBJECTIVES: Evaluate factors and reasons associated with switching from initial 
biologic disease-modifying anti-rheumatic drugs (bDMARDs) in Kaiser Permanente 
Southern California (KPSC) RA patients; to evaluate RA related healthcare resource 
utilization (HCRU) and cost associated with bDMARD switching. METHODS: A ret-
rospective database study from time period 01/01/2007 to 12/31/2012 was used to 
identify KPSC patient’s ≥ 18 years of age and with a diagnosis of RA (ICD-9 714.xx). 
The index date was defined as the first bDMARD prescription with no prior history 
of bDMARD use 12 months pre-index date. Patients were followed up for 12 months 
post-index and were categorized into a switch group and a non-switch group dur-
ing follow up. A multivariate regression analysis was conducted to evaluate factors 
associated with bDMARD switching. Chart notes were reviewed 30 days prior and 
30 days post bDMARD switch to identify reasons for switching. RA related HCRU 
and costs were calculated for 12 months pre/post-index for both groups. RESULTS: 
2,171 patients were identified (12% switchers, and 88% non-switchers). The aver-
age time for patients to switch was 110 days (SD + 95.5). Differences in base-
line characteristics included more use of corticosteroids, narcotics, and higher 
ER and outpatient visits in the switch group. Factors associated with bDMARD 
switching were: female gender, obesity, corticosteroids use, other conventional 
DMARD use, higher ER/outpatient use in the prior 6 months, and patients initi-
ated on Etanercept. Over 70% of patients switched due to adverse events, lack 
or loss of efficacy. Patients who switched had higher RA related cost during 12 
months pre/post-index compared to the non-switch group. CONCLUSIONS: This 
is a unique study that used robust data from an integrated healthcare system 
to evaluate reasons associated with bDMARD switching in this RA population. 
Reasons associated with bDMARD switching included medication adverse events, 
and lack/loss of efficacy; bDMARD switchers had significantly higher RA related 
costs.
PMS5
MetA-AnAlySiS of efficAcy And SAfety of denoSuMAB in 
PoStMenoPAuSAl oSteoPoroSiS
Xuan S.1, Ma J.2, Liu G.G.3
1Yale University, New Haven, CT, USA, 2University of Utah, Salt Lake City, UT, USA, 3Peking 
University, Beijing, China
